dystrophic-anagen effluvium occurring during pegylated interferon-α-2a/ ribavirin therapy

Introduction: various types of dermatological manifestations have been reported due to hepatitis c virus (hcv) infection and anti- hcv therapy. some of them have been described during ifn-based therapies. peg-ifn-α-2a/rbv combination is used as the international standard of treatment for hcv infection for a long time. the combination therapy yields an adverse-event profile similar to standard interferon (ifn) therapy. some of these adverse effects are rheumatologic, neuropsychiatric and dermatological manifestations including alopecia. case presentation: we reported a 43-year-old woman with dystrophic anagen effluvium (dae), rheumatoid arthritis and hashimoto thyroiditis, which were developed under the combination therapy for chronic hcv infection. conclusions: although some cases of alopecia areata (aa) and telogen effluvium (te) were reported in literature, no case of dae associated with peg-inf-α-2a /rbv combination therapy was reported previously.